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ABSTRACT
Objective: Fractures due to osteoporosis represent a serious burden on patients and healthcare sys-
tems. The objective of this review is to provide an overview of the anabolic agent abaloparatide (ABL)
for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Methods: A literature review was conducted using PubMed to identify articles focused on ABL pub-
lished prior to February 10, 2020, using the search term “abaloparatide”.
Results: ABL, a synthetic analog of human parathyroid hormone-related protein, increased bone min-
eral density (BMD), improved bone microarchitecture, and increased bone strength in preclinical and
clinical studies. The pivotal phase 3 trial ACTIVE and its extension (ACTIVExtend) demonstrated the effi-
cacy of initial treatment with ABL for 18months followed by sequential treatment with alendronate
(ALN) for an additional 24months to reduce the risk of vertebral, nonvertebral, clinical, and major
osteoporotic fractures and to increase BMD in postmenopausal women with osteoporosis.
Discontinuations from ACTIVE were slightly more common in ABL-treated patients due to dizziness,
palpitations, nausea, and headache. Post hoc analyses of ACTIVE and ACTIVExtend support the efficacy
and safety of ABL in relevant subpopulations including postmenopausal women with various baseline
risk factors, women 80 years, women with type 2 diabetes mellitus, and women with
renal impairment.
Conclusions: ABL is an effective and well-tolerated treatment for women with postmenopausal osteo-
porosis at high risk for fracture. Its therapeutic effects are sustained with subsequent ALN therapy.
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Introduction
Public health burden of osteoporosis and
related fractures
Osteoporosis, a disorder that often occurs with aging, is asso-
ciated with reduced bone mass, compromised bone strength,
and impaired bone quality, resulting in an increased risk of
fracture1,2. Postmenopausal women are at particular risk for
osteoporosis due to estrogen deficiency, with nearly one in
two women likely to experience an osteoporosis-related frac-
ture in their lifetime3. Over 2 million osteoporotic fractures
occur annually in the United States, and this number is pro-
jected to grow even larger, to 3 million by 20254,5.
Osteoporosis-related fractures are an important public
health concern because of related morbidity, mortality, and
cost. Excess mortality among patients with hip fractures is
10–20% in the year following such a fracture6,7 with as
many as two-thirds of patients failing to regain their prior
functional status7,8. Both clinical vertebral fractures (fractures
that come to immediate medical attention) and asymptom-
atic vertebral fractures (which account for more than
two-thirds of all vertebral fractures) are also associated with
substantial morbidity and mortality in postmeno-
pausal women9–11.
Osteoporosis-related fractures are also associated with a
significant economic burden. Indeed, hospitalizations for
osteoporotic fractures are more frequent than for stroke,
heart attack, or breast cancer (Figure 1)12. The burden of
osteoporotic fractures also includes the unmeasured but very
real economic costs due to impairment of such activities as
care of grandchildren or volunteer work by “retired” individu-
als who sustain a fracture, or loss of productivity for care-
givers taking care of a fracture patient. Despite this, studies
have shown that the vast majority of patients are not treated
for osteoporosis following a fracture13 and rates of
CONTACT Bruce Mitlak bmitlak@radiuspharm.com Clinical Development, Radius Health, Inc., 950 Winter Street, Waltham, MA 02451, USA
 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
www.cmrojournal.com
CURRENT MEDICAL RESEARCH AND OPINION
https://doi.org/10.1080/03007995.2020.1824897
Article RT-0344.R1/1824897
osteoporosis diagnosis and office-based DXA utilization have
declined in recent years14.
Medications approved for the treatment of osteoporosis
in the US include the anabolic agents teriparatide (TPTD),
abaloparatide (ABL), and romosozumab, and antiresorptive
drugs, including bisphosphonates, denosumab, estrogens,
and selective estrogen receptor modulators (SERMs).
Anabolic agents stimulate osteoblast production and func-
tion resulting in increased bone formation and improved
bone microstructure, mass, and strength15, whereas antire-
sorptive therapies inhibit osteoclast-mediated bone resorp-
tion16. Anabolic treatments are recommended for
postmenopausal women with osteoporosis at high risk for
fracture for a limited duration of treatment17,18. Although
most guidelines do not define an optimal sequence of treat-
ment, studies suggest the sequence in which anabolics and
antiresorptives are used can impact treatment effective-
ness1,19,20. In general, available data suggest anabolic agents
should precede, rather than follow, antiresorptives.
Clearly, timely treatment initiation and the appropriate
sequence of treatment are needed for patients at high risk
for osteoporotic fractures. The objective of this review is to
provide an overview of the anabolic agent ABL for the treat-
ment of postmenopausal women with osteoporosis.
Methods
A literature review was conducted using PubMed to identify
articles focused on ABL published in English prior to
February 10, 2020, using the search term “abaloparatide”.
Articles were excluded if they did not focus primarily on ABL
and postmenopausal osteoporosis. Review articles were
also excluded.
To ensure inclusion of the most up-to-date research
related to ABL, abstracts presenting data from the
Abaloparatide Comparator Trial In Vertebral Endpoints
(ACTIVE; the pivotal phase 3 trial for ABL) and its extension,
ACTIVExtend, at osteoporosis-relevant congresses were also
included in this review. Relevant abstracts from the
Endocrine Society (ENDO) annual meeting, the American
Society for Bone and Mineral Research (ASBMR) annual meet-
ing, the World Congress on Osteoporosis, Osteoarthritis, and
Musculoskeletal Diseases (WCO), and the American
Association of Clinical Endocrinology (AACE) annual meeting
from 2016 to 2019, inclusive, are included.
Results
ABL preclinical and early clinical development
Parathyroid hormone (PTH) and parathyroid hormone-related
protein (PTHrP) both signal through the PTH receptor type 1
(PTHR1) with important, but different, effects on bone devel-
opment and remodeling21–23. Studies have demonstrated
that PTH and PTHrP bind to different conformations of the
PTHR1 receptor with differing affinities22. PTH binds with
greater affinity than PTHrP22 to the G-protein uncoupled
conformation, R0, which is associated with prolonged cyclic
AMP signaling, while PTHrP and PTH bind with similar affin-
ities to the G protein-coupled RG conformation, which results
in shorter duration of cyclic AMP response22. Therefore, only
PTH results in sustained cyclic AMP production, which
involves receptor internalization and positive calcium allos-
tery23–26. Studies have shown that continuous cyclic AMP sig-
naling favors osteoclast formation and bone resorption while
intermittent signaling favors a net anabolic effect21,27–29;
however, whether this translates to clinically relevant differ-
ence with PTH and PTHrP ligands on bone resorption
remains to be determined.
ABL is a synthetic analog of human PTHrP (1–34) with
41% sequence homology to PTH (1–34) and 76% sequence
homology to PTHrP (1–34) (Figure 2) that binds more
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Figure 1. Unadjusted rates of hospitalizations for osteoporotic fractures compared with rates for myocardial infarction, stroke, and breast cancer in the United
States.12 MI, myocardial infarction; OF, osteoporotic fracture. Reprinted from Mayo Clin Proc, 90(1), Singer A, et al., Burden of illness for osteoporotic fractures com-
pared with other serious diseases among postmenopausal women in the United States, Pages No.53–62, Copyright (2015), with permission from Elsevier.
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selectively to the RG versus the R0 PTHR1 conformation30,31.
ABL binds to the R0 confirmation with an 80-fold weaker
affinity than that observed for TPTD and the affinities for the
RG versus R0 conformation differed by 1600-fold for ABL ver-
sus 12-fold for TPTD.
In preclinical studies, ABL increased bone mass and bone
formation and improved bone microarchitecture. These
results were correlated with increased bone strength in ovar-
iectomized (OVX) rats and cynomolgus monkeys30,32–35.
Specifically, 12months of ABL treatment in OVX rats led to
dose-dependent improvements in bone mass, geometry, and
strength with evidence of bone quality preservation or
improvement30,34. Studies in cultured cells and animal mod-
els have shown that the effects of ABL on bone may occur
with greater increase in markers of bone formation and less
resorptive activity, including reduced stimulation of factors
involved in bone resorption, compared with TPTD35–39. Less
resorptive activity was observed with ABL versus TPTD at the
same equimolar concentrations and at a 1:4 higher ration of
ABL to TPTD39. Another recent study directly compared the
in vivo and in vitro effects of TPTD and ABL, providing new
evidence that ABL exhibits greater osteoanabolic response
and higher cAMP stimulation and b-arrestin recruitment than
TPTD38. Taken together, these findings would suggest that
differences in cAMP stimulation by TPTD versus ABL could
be responsible for the distinct anabolic actions on bone.
In OVX cynomolgus monkeys, 16months of ABL treatment
increased bone formation, bone density, and bone strength
with no apparent effects on bone resorption or serum cal-
cium33. Bone quality was preserved at purely cortical sites
and was maintained or improved at trabecular-rich sites;
however, ABL did not increase cortical porosity. In a separate
study, TPTD was shown to increase bone resorption and cor-
tical porosity in a dose-dependent manner in OVX cynomol-
gus monkeys, however, the effects on cortical porosity did
not adversely affect bone strength40,41. PTH (1–84) has also
been shown to increase cortical porosity in OVX cynomolgus
monkeys, but only at the highest of three doses studied
(25mg per kg), which is estimated to result in 13-fold higher
exposure than the dose used in humans42,43.
As with all PTHR1 agonists, a dose-dependent increase in
the incidence of osteosarcoma has been observed in rats
treated chronically for up to 2 years with ABL at doses esti-
mated to result in 3-, 11-, and 22-fold greater exposure than
the 80 lg/day dose approved for short-term use in humans44.
The incidence of neoplastic changes in long-term rodent
toxicology studies was similar between ABL and TPTD.
Increased risk of osteosarcoma was not observed with TPTD
in cynomolgus monkeys45. Postmarketing surveillance has
not observed an association between TPTD treatment and
osteosarcoma in humans after more than 17 years of clinical
use46,47; no cases of osteosarcoma have been reported in
humans treated with ABL at approximately 2 years post-
launch (Radius Health, Inc.).
Early clinical trials in postmenopausal women with osteo-
porosis showed beneficial effects of ABL on BMD and tra-
becular bone score (TBS), an indirect measure of bone
microarchitecture48,49. In a 24-week, phase 2 dose-finding
study, 222 women with postmenopausal osteoporosis were
randomly assigned to receive daily subcutaneous injections
of placebo (PBO); ABL 20, 40, and 80mg; or TPTD 20 mg48.
BMD increased in a dose-dependent manner with ABL treat-
ment, and increases in BMD were greater with ABL versus
PBO at the lumbar spine (40mg and 80 mg, p< .001), femoral
neck (80mg, p¼.036), and total hip (80mg, p¼ .007). Increases
in total hip BMD were greater in the ABL 40 mg (p¼ .047)
and 80 mg (p¼ .006) groups compared with the group receiv-
ing TPTD. ABL also increased TBS versus PBO in the 20, 40,
and 80 mg groups (p< .001 for all groups at 24weeks)49.
Increase in TBS was also significantly greater with 80 mg ABL
versus TPTD (p¼ .04).
The proportion of participants who experienced treat-
ment-emergent adverse events (TEAEs) was similar across all
treatment groups. Most TEAEs were mild to moderate in
severity48. Overall, arthralgia and urinary tract infection (15%
each); bronchitis, influenza, and nasopharyngitis (9% each);
and anemia, back pain, dizziness, dyslipidemia, hypercalciuria,
and injection site hematoma (7% each) were the most com-
mon adverse events (AEs).
ABL pivotal trials: ACTIVE and ACTIVExtend
ACTIVE was the pivotal multicenter, multinational, double-
blind, PBO- and active-controlled, phase 3 fracture-preven-
tion trial for ABL in postmenopausal women with osteopor-
osis50. Osteoporosis was defined by BMD and/or fracture
criteria. A total of 2463 women aged 49–86 years with osteo-
porosis were randomized 1:1:1 to receive daily subcutaneous
injections of PBO, ABL 80 lg, or open-label active comparator
TPTD 20 mg for 18months (Figure 3). 1901 women com-
pleted the study (73.5% [n ¼ 606] in the ABL group, 77.6%
[n ¼ 637] in the placebo group, and 80.4% [n ¼ 658] in the
PTH1–34
(teriparatide)
PTHrP1–34
Abaloparatide
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X=Aib
41% identity to PTH (1–34) and 76% identity to PTHrP (1–34)
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Figure 2. Abaloparatide sequence identity with human PTH and PTHrP. Purple represents identity to PTH (1–34). Green represents identity to PTHrP (1–34). Blue
represents substitute residues in abaloparatide. Abbreviations. PTH, parathyroid hormone; PTHrP, parathyroid hormone-related protein.
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TPTD group). At the end of ACTIVE, participants who
received ABL or PBO were offered enrollment in the
ACTIVExtend extension study51,52. There were 1139 women
(92% of those eligible) enrolled in ACTIVExtend and treated
with ALN 70mg weekly for 24months. A 1-month rollover
period from the end of ACTIVE to enrollment in ACTIVExtend
was allowed.
ACTIVE
Groups were well matched at baseline with an overall mean
age of 68.8 years, mean spine and total hip BMD T-score of
2.9 and 1.9, respectively, prior vertebral fracture in 24%
of participants, and a history of nonvertebral fracture within
the past 5 years in 31% of participants50. Daily subcutaneous
administration of ABL 80 mg for 18months significantly
reduced the risk of new vertebral fractures by 86% versus
PBO, with new vertebral fractures occurring in only 0.6% of
participants in the ABL group versus 4.2% in the PBO group
(p< .001) (Figure 4)50. TPTD also reduced the risk of new ver-
tebral fractures by 80% versus PBO (p< .001).
In addition, nonvertebral time-to-event curves suggest
early fracture risk reduction with ABL (Figure 5). ABL signifi-
cantly reduced the risk of nonvertebral (by 43%), clinical (by
43%), and major osteoporotic (by 70%) fractures versus PBO.
In contrast, Kaplan-Meier estimated event rates for nonverte-
bral, clinical, and major osteoporotic fractures were not sig-
nificantly different with TPTD compared with PBO. Although
this study was not powered for a comparison between ABL
and TPTD, a reduction in the risk of major osteoporotic
ALN 70 mg weekly (N = 581)
ALN 70 mg weekly (N = 558)
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Figure 3. ACTIVE and ACTIVExtend study design51. Abbreviations. ABL, abaloparatide; ALN, alendronate; PBO, placebo; SC, subcutaneous; TPTD, teriparatide.
Adapted from Bone et al., J Clin Endocrinol Metab, August 2018, 103(8):2949–2957. Copyright 2018 CC BY License.
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Figure 4. Incidence of new vertebral fractures in ACTIVE (months 0–18)50. New vertebral fractures occurred in 0.6% of patients in the ABL group versus 4.2% in
the PBO group (RD versus PBO, 3.64 [95% CI, 5.42 to 2.10]; relative risk, 0.14 [95% CI, 0.05 to 0.39]; p< .001. New vertebral fractures occurred in 0.8% of
patients in the TPTD group (RD versus PBO, 3.38 [95% CI, 5.18 to 1.80]; relative risk, 0.20 [95% CI, 0.08 to 0.47]; p< .001). New vertebral fractures included
clinical and nonclinical fractures assessed by radiograph. *p< .001; ABL, abaloparatide; CI, confidence interval; PBO, placebo; RD, risk difference; RRR, relative risk
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4 P. D. MILLER ET AL.
fractures was observed with ABL versus TPTD, with major
osteoporotic fractures occurring in 1.5% of the ABL group
versus 3.1% of the TPTD group.
ABL treatment was associated with significantly increased
BMD versus PBO; BMD changes at 18months for ABL versus
PBO were 4.2 versus 0.1% at the total hip (treatment differ-
ence, 4.3% [95% CI, 3.9–4.6%; p< .001]), 3.6 versus 0.4% at
the femoral neck (treatment difference, 4.0% [95% CI,
3.6–4.5%; p< .001]), and 11.2 versus 0.6% at the lumbar
spine (treatment difference, 10.4% [95% CI, 9.8–11.0%;
p< .001]). Significant increases in total hip, femoral neck, and
lumbar spine BMD were also seen at 6months and
12months with ABL versus PBO. Improvements in BMD at
the total hip and femoral neck were significantly greater
with ABL than with TPTD at all time points, and at the lum-
bar spine significantly greater at 6 and 12months, but not
at 18months.
Changes in bone turnover markers with ABL treatment were
consistent with changes in BMD with ABL50,53. An early increase
(at 1month) in the bone formation marker serum procollagen
type 1N-terminal propeptide (s-PINP) was seen with both ABL
and TPTD. After 3months, s-PINP levels trended higher with
TPTD than with ABL, though levels remained above baseline
throughout 18months in both groups. Concurrently, serum C-
terminal telopeptide of type 1 collagen (s-CTX), a bone resorp-
tion marker, increased to a lesser extent with ABL versus TPTD
at all time points, supporting the hypothesis that ABL might be
associated with less bone resorption compared with TPTD. A
post hoc analysis to examine the relationship between early
markers of bone turnover and BMD found that changes in s-
PINP 3months posttreatment were correlated with subsequent
changes in lumbar spine BMD at 18months in both ABL-
treated and TPTD-treated participants in the ACTIVE trial53.
Absolute levels of s-PINP and s-CTX were lower with ABL com-
pared to TPTD; however, the balance between markers of bone
formation and resorption was similar, indicating that BMD
increases with ABL with less bone resorption. The balance of
bone formation and resorption with ABL resulted in earlier and
greater increases in BMD at the spine and total hip, which
remained greater at the hip over 18months.
No differences were seen in serious AEs between treat-
ment groups; however, more AEs leading to study discon-
tinuation occurred in the ABL group (9.9%) than in the TPTD
(6.8%) or PBO (6.1%) groups. AEs leading to discontinuation
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were generally mild to moderate in severity and included
nausea (1.6%), dizziness (1.2%), headache (1.0%), and palpita-
tions (0.9%), symptoms associated with vasodilation.
Orthostatic hypotension (a decrease in systolic blood pres-
sure of at least 20mmHg or diastolic blood pressure of at
least 10mmHg from a supine position to standing in a post-
dose measurement), an AE of special interest in the study,
occurred at a similar incidence across groups (ABL 17.1%,
PBO 16.4%, TPTD 15.5%). Hypercalcemia was a prespecified
study endpoint based on serum calcium concentrations
obtained both pre-injection and 4 h post-injection on day 1,
and months 1, 3, 6, 9, and 12; and pre-injection only at
month 18. Its incidence was lower with ABL (3.4%) versus
TPTD (6.4%) (risk difference, 2.96% [95% CI, 5.12 to
0.87]; p¼ .006), consistent with less bone resorption with
ABL. There was no evidence of increased cardiovascular risk
associated with hypercalcemia in the ABL or TPTD groups.
Finally, transiliac crest bone biopsies obtained between
months 12 and 18 in ACTIVE showed no adverse effects on
bone quality in participants treated with ABL or TPTD54.
ACTIVExtend
ACTIVExtend included patients from the two arms initially
treated with PBO or ABL, but not the open-label TPTD arm
of ACTIVE. The reductions in fracture risk achieved with
18months of ABL treatment in ACTIVE were sustained with
subsequent open-label ALN 70mg given orally once per
week for an additional 24months (cumulative 43months)51.
Notably, during the extension wherein all subjects received
open-label ALN, the relative risk reduction for vertebral frac-
tures in the original active ABL group, versus those who had
received PBO, demonstrated a persistent advantage. After
6months of ALN monotherapy (between months 19–25), no
new vertebral fractures were reported in the group who
received ABL followed by ALN (ABL/ALN) compared with 7 in
the group who received PBO followed by ALN (PBO/ALN). At
cumulative month 25, there was an 87% relative risk reduc-
tion in the incidence of new vertebral fractures in the ABL/
ALN group versus the PBO/ALN group (p < .001) and, at
cumulative month 43, an 84% relative risk reduction
(p < .001)52 (Figure 6). Participants in the ABL/ALN group
versus those in the PBO/ALN group also demonstrated sig-
nificant reductions in the incidence of nonvertebral fractures,
clinical fractures, and major osteoporotic fractures at cumula-
tive month 25 and cumulative month 43 (Figure 7). Although
the study was not originally designed to assess hip fracture
risk, a supplemental analysis in the ACTIVE intent-to-treat
(ITT) plus ACTIVExtend ITT populations was done for regula-
tory authorities. No hip fractures were reported in the ABL/
ALN group versus 5 in the PBO/ALN group.
Gains in BMD at the lumbar spine, total hip, and femoral
neck that occurred with ABL treatment versus PBO in ACTIVE
were sustained and further enhanced during 24months of
monotherapy with ALN in ACTIVExtend.
The overall incidence of AEs, including severe and serious
AEs, was similar between groups while all participants received
the same treatment (ALN). The most commonly reported AEs
were arthralgia, upper respiratory tract infection, and back pain.
ACTIVE and ACTIVExtend post hoc analyses
A number of post hoc analyses of ACTIVE and ACTIVExtend
have been conducted to further elucidate the efficacy of ABL
in postmenopausal women with osteoporosis53,55–68.
These include further exploration of the BMD effects of
ABL in ACTIVE and ACTIVExtend. A prespecified responder
analysis58,68 found that a significantly greater proportion of
Figure 6. Incidence of new vertebral fractures in ACTIVE/ACTIVExtend (months 0–25 and months 0–43)51,52. New vertebral fractures occurred in 0.6% of patients in
the ABL/ALN group versus 4.4% in the PBO/ALN group at month 25 (relative risk, 0.13; p< .001) and 0.9% of patients in the ABL/ALN group versus 5.6% in the
PBO/ALN group at month 43 (relative risk, 0.16; p< .001). p< .001; Abbreviations. ABL/ALN, abaloparatide followed by alendronate; PBO/ALN, placebo followed
by alendronate; RRR, relative risk reduction. Adapted from Bone et al, J Clin Endocrinol Metab, August 2018, 103(8):2949–2957, under the CC BY License. Adapted
from Mayo Clin Proc., 92/2, Cosman F, et al. Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate
in postmenopausal women with osteoporosis: results of the ACTIVExtend trial. p. 200–210, Copyright (2017) with permission from Elsevier.
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Figure 7. Time to event of (a) nonvertebral, (b) clinical, and (c) major osteoporotic fractures in ACTIVE/ACTIVExtend (months 0–43)51. Kaplan–Meier curves of time
to the first (a) nonvertebral, (b) clinical, and (c) major osteoporotic fracture. Abbreviations. ABL/ALN, abaloparatide followed by alendronate; PBO/ALN, placebo fol-
lowed by alendronate. Reproduced from Bone et al, J Clin Endocrinol Metab, August 2018, 103(8):2949–2957, under the CC BY License.
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participants treated with ABL compared with both PBO and
TPTD had BMD gains at all three anatomic sites (total hip,
lumbar spine, and femoral neck) at each threshold (>0, >3.0,
and >6.0%) in ACTIVE58. This trend continued in
ACTIVExtend with significantly more participants in the ABL/
ALN group experiencing increases of >0, >3.0, and >6.0% at
each anatomical site compared with the PBO/ALN group at
43months (p< .001)68. In addition, the effect of ABL on wrist
BMD, including anatomical sites with a high proportion of
trabecular bone (the ultra distal radius) and cortical bone (1/
3 radius) was examined56,65. ABL significantly increased BMD
at the ultra distal radius versus PBO and TPTD at 18months
in ACTIVE56. BMD at the 1/3 distal radius was not signifi-
cantly different with ABL versus PBO but declined with TPTD
versus ABL and PBO. The BMD gains at the ultra distal radius
following treatment with ABL in ACTIVE were maintained
over the subsequent 24months of treatment with ALN in
ACTIVExtend65. Although not significantly different due to
low numbers of events, the incidence of wrist fracture in
ACTIVE and ACTIVExtend was numerically lower with ABL/
ALN versus PBO/ALN.
Post hoc analyses of ACTIVE have also examined the efficacy
of ABL in various subpopulations including based on patient
baseline risk, age, in patients with renal impairment, in patients
with type 2 diabetes, and across geographic and ethnic sub-
groups (Table 1). The fracture risk reduction and BMD increases
observed in ACTIVE and ACTIVExtend were found to be con-
sistent regardless of participant baseline fracture risk64,66
(Figure 8). Fracture risk reduction was also similar across a
wide range of baseline fracture probabilities, as assessed by
FRAX in women from ACTIVE62, including in participants at
high risk of fracture (N ¼ 1400) based on the Committee for
Medicinal Products for Human Use (CHMP) guidelines for clin-
ical trial enrollment (a baseline 10-year risk of major osteopor-
otic fracture 10% or hip fracture 5%)60. Fracture risk
reduction with ABL was also consistent in participants from
ACTIVE across geographic region subgroups (North America,
South America, Europe, and Asia) and regardless of ethnicity
subgroup (Hispanic or Latino or other)67.
In women aged 80 years (n ¼ 94), ABL significantly
increased BMD at the total hip, femoral neck, and lumbar
spine to a similar extent as in the overall ACTIVE popula-
tion63. These effects were sustained with ALN treatment in
ACTIVExtend55. The overall number of fractures in both
ACTIVE and ACTIVExtend was too low in this elderly popula-
tion to draw any conclusions. The safety profiles were similar
for the ACTIVE and ACTIVExtend overall populations and the
80 years subgroup. Importantly, in a post hoc analysis of
ACTIVE that examined the impact of renal impairment on
the efficacy and safety of ABL, there were no detectable dif-
ferences in BMD changes, fracture risk reduction, and AEs in
participants with different degrees of baseline renal function
(eGRF < 60, 60 to < 90, and 90mL/min)57.
Finally, in the subgroup of postmenopausal women with
T2DM in ACTIVE (n ¼ 198), ABL treatment resulted in signifi-
cant improvements in BMD at total hip, femoral neck, and
lumbar spine compared with PBO, consistent with the overall
ACTIVE population59. Significant (p< .001) improvements in
TBS at the lumbar spine (3.72 versus 0.56%) were observed
with ABL versus PBO at 18months, suggesting improvements
in bone microarchitecture, which may be impaired in individ-
uals with T2DM. Results were similar for TPTD versus PBO.
Fracture event numbers were low due to the small size of
this subpopulation and not significantly different
between groups.
ABL compared with other osteoporosis treatments
Current evidence suggests that anabolic agents induce a
more rapid and greater reduction in both vertebral and non-
vertebral fractures than seen with antiresorptive agents.
However, head-to-head blinded comparisons of ABL versus
other osteoporosis therapies are not available. Summarized
above is the only ABL study that utilized TPTD as an active
comparator (treatment assignments were randomized but
open-label).
In addition, the efficacy of ABL compared with ALN has
been indirectly examined in a post hoc analysis of ACTIVE
Table 1. Efficacy and safety of ABL in various subpopulations from ACTIVE and ACTIVExtend.
The efficacy and safety of ABL are consistent with the overall ACTIVE/ACTIVExtend population in the following subpopulations
Patient baseline fracture risk64,66
 BMD T-score of the lumbar spine, total hip, and femoral neck (–2.5 versus >–2.5 and –3.0 versus >–3.0)
 History of nonvertebral fracture (yes versus no)
 Prevalent vertebral fracture (yes versus no)
 Age (<65 versus 65 to <75 versus 75 years)
Fracture risk as assessed by FRAX62
Fracture risk based on CHMP thresholds60
 Baseline 10-year risk of major osteoporotic fracture 10% or hip fracture 5%
The elderly55,63
 Aged 80 years
Patients with renal impairment57
 Baseline eGFR of 90mL/min (stage I CKD)
 Baseline eGFR 60mL/min to ˂90mL/min (stage II CKD)
 Baseline eGFR 30mL/min to <60mL/min (stage III CKD)
Patients with T2DM59
Across geographic and ethnic subgroups67
 North America, South America, Europe, and Asia
 Hispanic, Latino, or other
Abbreviations. BMD, bone mineral density; CHMP, Committee for Medicinal Products for Human Use; CKD, chronic kidney disease;
eGFR, estimated glomerular filtration rate; FRAX, fracture risk assessment tool; T2DM, type 2 diabetes mellitus.
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and ACTIVExtend, in which the effectiveness of ABL treat-
ment in ACTIVE was compared with ALN treatment in
ACTIVExtend in postmenopausal women with osteoporosis61.
Cross-group comparison of the incidence of new vertebral
fractures between the ABL group during ACTIVE and the
PBO/ALN group during ACTIVExtend showed a significant
decrease with initial treatment with ABL versus initial treat-
ment with ALN. These findings further support the use of
the anabolic agent prior to the antiresorptive agent in
sequential treatment. Both short-term and long-term results
Lumbar spine BMD T-score
Total hip BMD T-score
Femoral neck BMD T-score
Prevalent vertebral fracture
Prior nonvertebral fracture
Age, years
≤−2.5
>−2.5
≤−3.0
>−3.0
≤−2.5
>−2.5
≤−3.0
>−3.0
 
≤−2.5
>−2.5
≤−3.0
>−3.0
 
Yes
No
 
Yes
No
 
<65
65 to <75
≥75
PBO
n/N
23/543
7/168
17/370
13/341
11/174
19/537
3/55
27/656
11/210
19/501
5/71
25/640
15/165
15/546
22/349
8/362
8/131
18/459
4/121
ABL-SC
n/N
3/507
1/183
3/361
1/329
1/155
3/535
1/50
3/640
2/198
2/492
0/60
4/630
1/147
3/543
3/343
1/347
1/126
1/437
2/127
 
RR (95% CI)
0.14 (0.04, 0.46)
0.13 (0.02, 1.05)
0.18 (0.05, 0.61)
0.08 (0.01, 0.61)
0.10 (0.01, 0.78)
0.16 (0.05, 0.53)
0.37 (0.04, 3.41)
0.11 (0.03, 0.37)
0.19 (0.04, 0.86)
0.11 (0.03, 0.46)
NA
0.16 (0.06, 0.46)
0.07 (0.01, 0.56)
0.20 (0.06, 0.69)
0.14 (0.04, 0.46)
0.13 (0.02, 1.04)
0.13 (0.02, 1.02)
0.06 (0.01, 0.44)
0.48 (0.09, 2.55)
 Interaction
P valuea
0.960
 
0.493
 
0.699
 
0.356
 
0.588
 
0.403
 
0.371
 
 
0.984
 
 
0.209
 
 
 
0.01 RR, 95% CI 1.0 4.0
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Femoral neck BMD T-score
Prevalent vertebral fracture
Prior nonvertebral fracture
Age, years
≤−2.5
>−2.5
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≤−2.5
>−2.5
≤−3.0
>−3.0
 
≤−2.5
>−2.5
≤−3.0
>−3.0
 
Yes
No
 
Yes
No
 
<65
65 to <75
≥75
PBO
n/N
26/631
7/190
21/431
12/390
12/199
21/621
2/65
31/755
11/242
22/578
4/81
29/739
10/188
23/632
19/416
14/405
9/161
14/512
10/148
ABL-SC
n/N
14/603
4/220
7/440
11/383
6/185
12/637
1/56
17/766
5/240
13/582
3/76
15/746
4/177
14/647
11/405
7/419
3/152
12/517
3/155
 
HR (95% CI)b
0.58 (0.30, 1.12)
0.53 (0.16, 1.82)
0.34 (0.14, 0.79)
0.98 (0.43, 2.21)
0.56 (0.21, 1.49)
0.58 (0.28, 1.18)
0.58 (0.05, 6.42)
0.56 (0.31, 1.02)
0.48 (0.17, 1.38)
0.61 (0.31, 1.21)
0.86 (0.19, 3.83)
0.53 (0.29, 0.99)
0.44 (0.14, 1.41)
0.62 (0.32, 1.20)
0.60 (0.29, 1.27)
0.52 (0.21, 1.28)
0.35 (0.09, 1.29)
0.90 (0.42, 1.96)
0.29 (0.08, 1.07)
 Interaction
P valuec
0.879
 
0.082
 
0.951
 
0.968
 
0.707
 
0.567
 
0.622
 
 
0.790
 
 
0.230
 
 
 
0.05 HR, 95% CI 1.0 7.0
(a)
(b)
Figure 8. Relative risk ratio of new vertebral fractures (a) and hazard ratio of nonvertebral fractures (b) with abaloparatide versus placebo by prespecified subgroup
in ACTIVE64. aBased on the Breslow-Day test for homogeneity of odds ratios between ABL-SC and placebo groups across the subgroup categories. bHazard ratios
were calculated within each subgroup category. cBased on the Cox proportional hazard model that includes main effects of treatment and subgroup and treat-
ment-by-subgroup interaction. Lowercase n refers to the number of participants in each category with a new vertebral (a) or nonvertebral fracture (b). Uppercase
N’s refer to the population size for each category. Abbreviations. ABL, abaloparatide; BMD, bone mineral density; CI, confidence interval; HR, hazard ratio; PBO, pla-
cebo; RR, relative risk; SC, subcutaneous. Reprinted with permission from Cosman et al. Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in
Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors J Bone Miner Res. 2017;32(1):17–23. doi:10.1002/jbmr.2991. Copyright
2016 American Society for Bone and Mineral Research, John Wiley & Sons Inc. All rights reserved.
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were better with treatment initiated with ABL and followed
by ALN, than with primary ALN treatment.
The effectiveness of ABL has been further evaluated by
determining the number needed to treat (NNT) to prevent one
additional vertebral, nonvertebral, clinical, or major osteopor-
otic fracture in patients treated with ABL or TPTD using data
from ACTIVE69. The NNT to prevent one additional vertebral
fracture was 28 for ABL and 30 for TPTD based on 18months
of treatment in ACTIVE. The NNT was also lower for ABL versus
TPTD for nonvertebral fractures (55 versus 92), clinical fractures
(37 versus 59), and major osteoporotic fractures (34 versus 75).
These data illustrate the relative efficacy of ABL and TPTD but
are specific to the ACTIVE study population.
Future and ongoing studies
Future studies and ongoing trials with ABL include the col-
lection of real-world data in patients treated with ABL to fur-
ther establish the effectiveness, safety, and cost of care of
ABL in the real-world setting; evaluation of the effects of ABL
on indices of bone formation and resorption (NCT03710889);
evaluation of the efficacy and safety of ABL in men
with osteoporosis (NCT03512262); and evaluation of the effi-
cacy and safety of an intradermal formulation of ABL
(NCT01674621), the first anabolic transdermal delivery system
for the potential treatment of postmenopausal osteoporosis
to begin a phase 3 clinical trial.
Conclusions
Osteoporosis and associated fractures represent a serious
burden on patients and healthcare systems. Despite current
treatment options, an unmet need exists in terms of patient
education and awareness, diagnosis of osteoporosis, and
treatment of patients with osteoporosis.
The results of the ACTIVE trial clearly establish the efficacy
and tolerability of ABL across a spectrum of postmenopausal
women at high risk of fracture. The results of ACTIVE and
ACTIVExtend also demonstrate the efficacy of sequential
treatment consisting of initial anabolic treatment with ABL
for 18months to increase bone mass and reduce the risk of
vertebral and nonvertebral fractures, followed by treatment
with the antiresorptive agent ALN for up to two additional
years. The data support a sequential approach to therapy
that would start with ABL and be followed by an antiresorp-
tive agent. Post hoc analyses of ACTIVE and ACTIVExtend
support the safety and efficacy of sequential treatment with
ABL followed by ALN in a variety of patient types.
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